

<p>Substitute for form 1449A/PTO</p> <p><b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b></p> <p>(use as many sheets as necessary)</p>		Complete if Known	
		Application Number	PTO
		Filing Date	5/22/03
		First Named Inventor	David WALLACH
		Group Art Unit	1644
		Examiner Name	
		Attorney Docket Number	WALLACH=10D
Sheet	1	of	4

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A/PTO				Comple <sup>t</sup> if Known	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				Application Number	
(use as many sheets as necessary)				Filing Date	
				First Named Inventor	David WALLACH
				Group Art Unit	1644
				Examiner Name	
Sheet	2	of	4	Attorney Docket Number	WALLACH=10C

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published			T <sup>2</sup>
	AL	BALAVOINE et al, "Prostaglandin E <sub>2</sub> and Collagenase Production by Fibroblasts and Synovial Cells Is Regulated by Urine-Derived Human Interleukin 1 and Inhibitor(s)", <u>J Clin Invest</u> 78:1120-1124 (1986)			
	AM	BEUTLER et al, "Passive Immunization against Cachectin/Tumor Necrosis Factor Protects Mice from Lethal Effect of Endotoxin", <u>Science</u> 229:869-871 (1985)			
	AN	BEUTLER et al, "Cachectin: More than a Tumor Necrosis Factor", <u>New Eng J Med</u> 316(7):379-385 (1987)			
	AO	BEUTLER et al, <u>Tumor Necrosis Factors</u> ..., Raven Press, New York, pp. 145, 383 (1992)			
	AP	BIGDA et al, "Dual Role of the p75 Tumor Necrosis Factor (TNF) Receptor in TNF Cytotoxicity", <u>J Exp Med</u> 180:445-460 (1994)			
	AQ	BROCKHAUS et al, "Monoclonal Antibodies against the TNF-Receptor Inhibit ...", 2 <sup>nd</sup> Int'l Conf. Tumor Necrosis Factor and Related Cytokines, Jan 15-20, 1989, p. 140			
	AR	BROCKHAUS et al, "Identification of two types of tumor necrosis factor receptors on human cell lines by monoclonal antibodies", <u>Proc Natl Acad Sci U S A</u> 87(8):3127-3131 (1990)			
	AS	CHEN et al, "Mapping the domain(s) critical for the binding of human tumor necrosis factor-alpha to its two receptors", <u>J Biol Chem</u> 270(6):2874-2878 (1995) (Abstract)			
	AT	CREASEY et al, "Biological Effects of Recombinant Human Tumor Necrosis Factor and Its Novel Muteins on Tumor and Normal Cell Lines", <u>Cancer Research</u> 47:145-149 (1987)			
	AU	ENGELMANN et al, "Two Tumor Necrosis Factor-binding Proteins Purified from Human Urine", <u>J Biol Chem</u> 265(3):1531-1536 91990)			
	AV	HARRIS et al, "Therapeutic antibodies - the coming of age", <u>TIBTECH</u> 11:42-44 (1993)			
	AW	HIGUCHI et al, "Modulation of two forms of tumor necrosis factor receptors and their cellular response by soluble receptors and their monoclonal antibodies", <u>J Biol Chem</u> 267(29):20892-20899 (1992)			

Examiner Signature		Date Considered
--------------------	--	-----------------

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A/PTO				Complete if Known	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				Application Number	
(use as many sheets as necessary)				Filing Date	
Sheet	3	of	4	First Named Inventor	David WALLACH
				Group Art Unit	1644
				Examiner Name	
				Attorney Docket Number	WALLACH=10C

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published			T <sup>2</sup>
	AX	HOHMANN et al, "Two Different Cell Types Have Different Major Receptors for Human Tumor Necrosis Factor (TNFalpha)", <u>J Biol Chem</u> 264(25):14927-14934 (1989)			
	AY	HOHMANN et al, "Two Different Cell Types Have Different Major Receptors for Human Tumor Necrosis Factor (TNFalpha)", 2 <sup>nd</sup> Int'l Conf. Tumor Necrosis Factor and Related Cytokines, Jan 15-20, 1989, p. 143			
	AZ	LOETSCHER et al, "Purification and partial amino acid sequence analysis of two distinct tumor necrosis factor receptors from HL60 cells", <u>J Biol Chem</u> 265(33):20131-20138 (1990)			
	BA	NATANSON et al, "Selected Treatment Strategies for Septic Shock Based on Proposed Mechanisms of Pathogenesis", <u>Annals of Int Med</u> 120(9):771-783 (1994)			
	BB	PARRILLO JE, "Pathogenetic Mechanisms of Septic Shock", <u>New Eng J Med</u> 328(20):1471-1477 (1993)			
	BC	PEETRE et al, "A tumor necrosis factor binding protein is present in human biological fluids", <u>Eur J Haematol</u> 41:414-419 (1988)			
	BD	SCHALL et al, "Molecular Cloning and Expression of a Receptor for Human Tumor Necrosis Factor", <u>Cell</u> 61:361-370 (1990)			
	BE	SECKINGER et al, "A Human Inhibitor of Tumor Necrosis Factor alpha", <u>J Exp Med</u> 167:1511-1516 (1988)			
	BF	SMITH et al, "A Receptor for Tumor Necrosis Factor Defines an Unusual Family of Cellular and Viral Proteins", <u>Science</u> 248:1019-1023 (1990)			
	BG	STAUBER et al, "Human Tumor Necrosis Factor-alpha Receptor", <u>J Biol Chem</u> 263(35):19098-19104 (1986)			
	BH	TRACEY et al, "Shock and Tissue Injury Induced by Recombinant Human Cachectin", <u>Science</u> 234:470-474 (1986)			
	BI	TRACEY et al, "Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia" <u>Nature</u> 330:662-664 (1987)			

Examiner Signature		Date Considered
--------------------	--	-----------------

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A/PTO				Complete if Known	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(use as many sheets as necessary)</i>				Application Number	
				Filing Date	
				First Named Inventor	David WALLACH
				Group Art Unit	1644
				Examiner Name	
				Attorney Docket Number	WALLACH=10C
Sheet	4	of	4		

## OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.